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Abstract
Objectives: Health benefits and costs of combined reduced-antigen-content tetanus, diphtheria, and pertussis (Tdap)
immunization among adults $65 years have not been evaluated. In February 2012, the Advisory Committee on
Immunization Practices (ACIP) recommended expanding Tdap vaccination (one single dose) to include adults$65 years not
previously vaccinated with Tdap. Our study estimated the health and economic outcomes of one-time replacement of the
decennial tetanus and diphtheria (Td) booster with Tdap in the 10% of individuals aged 65 years assumed eligible each year
compared with a baseline scenario of continued Td vaccination.
Methods: We constructed a model evaluating the cost-effectiveness of vaccinating a cohort of adults aged 65 with Tdap, by
calculating pertussis cases averted due to direct vaccine effects only. Results are presented from societal and payer
perspectives for a range of pertussis incidences (25–200 cases per 100,000), due to the uncertainty in estimating true annual
incidence. Cases averted were accrued throughout the patient ’s lifetime, and a probability tree used to estimate the clinical
outcomes and costs (US$ 2010) for each case. Quality-adjusted life-years (QALYs) lost to acute disease were calculated by
multiplying cases of mild/moderate/severe pertussis by the associated health-state disutility; QALY losses due to death and
long-term sequelae were also considered. Incremental costs and QALYs were summed over the cohort to derive incremental
cost-effectiveness ratios. Scenario analyses evaluated the effect of alternative plausible parameter estimates on results.
Results: At incidence levels of 25, 100, 200 cases/100,000, vaccinating adults aged 65 years costs an additional $336,000,
$63,000 and $17,000/QALY gained, respectively. Vaccination has a cost-effectiveness ratio less than $50,000/QALY if
pertussis incidence is .116 cases/100,000 from societal and payer perspectives. Results were robust to scenario analyses.
Conclusions: Tdap immunization of adults aged 65 years according to current ACIP recommendations is a cost-effective
health-care intervention at plausible incidence assumptions.
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Introduction
Although the incidence of pertussis substantially declined
immediately following the introduction of reduced-antigen-content
tetanus, diphtheria and acellular pertussis (Tdap) vaccination
recommendations in 1997 and 2005, thereafter rates have steadily
increased to the point that pertussis causes a significant burden of
disease in the US [1,2].
In 2005, the Advisory Committee on Immunization Practices
(ACIP) recommended that adolescents 11–18 years of age
(preferably at age 11–12 years) and adults aged 19–64 years
should receive a single dose of Tdap vaccine, instead of the
standard tetanus and reduced-antigen-content diphtheria (Td)
decennial booster [1]. Subsequently, in October 2010, ACIP
recommended expanded use of Tdap, advising that children aged
7 through 10 years not previously fully vaccinated against pertussis
receive a single dose of Tdap, and that adults $65 years who have
close contact with an infant receive a single dose of Tdap if they
have not previously received the booster [3]. Despite recommen-
dations, Tdap coverage remains relatively low at 56% for the
adolescent booster and ,6% for the adult booster as of 2010 [4].
Since 2007, pertussis incidence has been increasing and
continues to remain higher than in the 1990 s [2]. It is unclear
whether this recent increase in incidence reflects changes in the
epidemiology or in disease reporting. Although pertussis is
nationally notifiable, many cases are believed to go unrecognized
and/or unreported [5], so the true incidence of disease is
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uncertain. Serologic studies have suggested that the true incidence
in adults may be more than 100 times the incidence reported to
the Centers for Disease Control and Prevention (CDC) [6,7].
Despite this uncertainty, current evidence clearly suggests that
recent vaccination practices have not completely controlled the
risk of pertussis infection.
In February 2012 ACIP extended the age range for its
recommendation of administration of a single dose Tdap vaccine
to all adults (including those $65 years) and removed limits on the
interval since last tetanus or diphtheria toxoid-containing vaccine,
reflecting the belief that additional Tdap vaccination in the
population aged $65 may yield additional benefits in disease
prevention [8].
Two Tdap vaccines are licensed in the US, BoostrixH and
AdacelH. BoostrixH, manufactured by GlaxoSmithKline, is indicated
for individuals 10 years of age and older. AdacelH, manufactured
by Sanofi Pasteur, is indicated for individuals 11–64 years of age.
The current analysis was conducted to assess the impact of the new
ACIP recommendation for Tdap vaccination in the population
aged $65 years, using a static model of a cohort of adults
vaccinated at 65 years.
Model Overview and Structure
The economic model (Figure 1–2) was constructed in Microsoft
ExcelH. The model assesses the cost-effectiveness of vaccinating a
cohort of adults aged 65 years with Tdap, by calculating pertussis
cases averted due to direct vaccine effects only. Results were
evaluated from the societal and the payer perspectives. The
societal perspective, which is consistent with the Reference Case
recommendations of the US Panel on Cost-Effectiveness in Health
and Medicine [9], considers both direct medical costs of pertussis
treatment and direct non-medical costs of patient ’s time in
hospital. The payer perspective considers only direct medical-care
costs.
The cost-effectiveness of the intervention was estimated by
calculating the incremental costs and outcomes associated with a
strategy of vaccinating adults aged 65 years with Tdap versus Td.
The same proportion (10%) of the 65-year-old cohort was
vaccinated under both strategies. Tdap vaccinated and Td
vaccinated cohorts were followed in the model for 35 years using
annual cycles (adjusted for age-specific mortality [10]). A scenario
analysis was conducted using a 10-year model time horizon.
We estimated the yearly probability of protection from pertussis,
assuming that vaccine protection wanes at a constant annual rate,
(i.e., following an exponential distribution), to determine the
proportion of vaccinated individuals who remained protected at
each age. Cases averted each year were calculated as the Tdap
vaccine efficacy multiplied by the number of individuals protected
at each age, multiplied by the incidence of pertussis. Cases averted
were accrued throughout the remaining lifetime of the cohort.
Cases were stratified by severity, where all severe and moderate
cases were treated and a proportion of mild cases were untreated
(Figure 2).
The model was used to estimate the total number of pertussis
cases avoided, quality-adjusted life-years (QALYs) gained, and
total direct medical and non-medical costs averted.
Model Inputs
Model inputs were obtained from publicly-available data and
peer-reviewed publications listed in Table 1.
Pertussis Incidence. In the adult population, pertussis is
widely under-recognized and underreported. While the available
but limited studies of pertussis incidence in adults report a wide
range of incidence between 66–500 cases/100,000 [11], fewer
than 5 cases/100,000 are reported to the CDC [2]. Recent
outbreaks in California and Washington State provided incidence
estimates that ranged widely from no cases to more than 400/
100,000 in selected counties or age groups [12,13]. Due to this
uncertainty in the true pertussis incidence in adults $65 years,
outcomes were assessed at different incidence rates (25, 50, 100,
150, and 200 cases/100,000) consistent with previously published
models [14]. Incidence rates are also consistent with the rate used
in a cost-effectiveness model of Tdap in adults aged $65 years
conducted by the CDC (104 cases/100,000) [11].
Vaccination and Disease Outcomes. Weassumed that 10%
of the population aged 65 years old will receive Tdap in the
intervention group and Td in the comparison group; this is
consistent with an equal portion of the population becoming eligible
for the decennial Td booster each year. Tdap vaccine efficacy in the
base case was estimated to be 89%. Tdap efficacy was not directly
measured but estimated via immunobridging to an infant DTaP
efficacy study (InfanrixH, GlaxoSmithKline) [15]. In the study used
for efficacy bridging, vaccine efficacy was shown to be 89%. A
scenario analysis was conducted assuming 77%efficacy based on the
lower limit of the 95% confidence interval in the DTaP vaccine
efficacy trial [13]. Waning immunity is assumed to occur at a
constant rate, with a mean duration of protection of 8 years
(Figure 3) [16]. Scenario analyses were conducted with alternative
duration of protection estimates of 6 and 10 years.
We classified each case generated by the model as severe
(requiring hospitalization), moderate (non-hospitalized cases with
symptoms of paroxysmal cough), or mild (non-hospitalized cases
without paroxysmal cough). In the base-case, the distribution of
cases by severity was assumed to be the same for all incidence
levels. The proportion of severe cases was based on hospitalization
rates reported to CDC among reported cases [5]. The proportion
of mild cases was based on the percentage of reported cases
without paroxysmal cough [5]. The proportion of moderate cases
Figure 1. Vaccination, waning protection and pertussis cases in a cohort aged 65 years.
doi:10.1371/journal.pone.0067260.g001
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was assumed to be those not classified as severe or mild. A scenario
analysis was conducted in which the distribution of cases by
severity was dependent on overall incidence level, similar to a
published cost-effectiveness study of pertussis vaccination in adults
aged 20–64 years [12].
Patients with severe pertussis are at risk of encephalopathy or
death. We used probability of encephalopathy to estimate loss of
quality of life associated with long-term disability in addition to the
loss of QALYs due to death. We estimated that 33% of
encephalitis cases would result in permanent sequelae, consistent
with encephalopathy [17]. The probabilities of encephalopathy or
death among severe cases were based on 1997–2000 data for
reported hospitalized cases [16]. an alternative assumption of no
cases of encephalopathy was also included as a scenario analysis.
A proportion of mild cases was assumed to receive medical
treatment; due to the limited available data, we assumed that the
proportion of mild pertussis cases seeking treatment is the same as
the proportion of influenza patients with an outpatient visit [18].
Utilities. Utility values, preference-based measures of quality-
of-life ranging from 0 to 1, that are used to calculate QALYs, were
obtained from the published literature [15,19]. Disutilities of mild,
moderate, and severe pertussis and encephalopathy were used to
estimate the QALY loss associated with acute pertussis by
multiplying the associated decrement by the time spent in the
health state (Table 1). Total duration of illness (87 days), obtained
from published literature [15], was assumed to be the same for
severe, moderate, and mild diseases. A mild case received the mild
symptom disutility for the full length of illness. Moderate cases
received two weeks of moderate symptom disutility followed by
mild symptom disutility for the remaining days of illness. A severe
case received two weeks of severe symptom disutility followed by
mild symptom disutility for the remaining days of illness. In
addition, patients with encephalopathy were assumed to receive
the disutility for encephalopathy for the remainder of their
lifetime. Loss of utility due to death was based on age-specific US
population norms estimated by Hanmer and colleagues, which
reflect decreasing health-related quality-of-life at older ages [20].
Total QALYs lost due to death or encephalopathy were calculated
as the discounted (at 3% per annum) present values of the lost
utility streams over the remaining expected lifetime, based on age-
specific life expectancy [10] at the time of the event.
Costs. Direct medical costs included vaccine costs and acute
costs of treating severe, moderate, and mild pertussis (Table 1).
Vaccine cost was obtained from the CDC vaccine price list [21]
based on the private incremental cost of Tdap versus Td. We
assumed that adults receive the private price and were
administered Tdap in place of their decennial Td booster;
therefore no additional administration fee was considered, and
only the marginal acquisition cost of Tdap versus Td was
counted. Costs of vaccine adverse events, weighted by the
probabilities of occurrence (incremental to Td adverse events),
were also included [12]. Scenario analyses were conducted
assuming public and mixed public and private (weighted by the
proportion who receive the vaccine at public cost) [22]
incremental vaccine costs. As appropriate, costs were converted
to 2010 U.S. dollars using the medical component of the
Consumer Price Index [23].
The cost of treating a mild case was estimated as the cost of an
antibiotic regimen (azithromycin) [24,25] and the cost of a level 2
physician visit [26]. Cost of treating a moderate case was based on
a prospective study of pertussis morbidity among families in a
community setting, which included physician visits, emergency
room visits, laboratory, and medication costs [27]. The cost of
treating a severe case of pertussis was based on total hospitalization
cost, including all accommodations (e.g., routine, intensive care
unit, nursery), ancillary (e.g., pharmacy, laboratory, imaging), and
physician services [28]. Hospitalization costs were obtained from a
published study of pertussis hospitalizations and included hospi-
talized cases due to pertussis complications such as pneumonia,
convulsions, apnea, encephalopathy, and acute respiratory
distress, failure, or arrest [23]. Because the acute cost of
encephalopathy was included in the hospitalization cost, it was
not estimated separately. No long-term medical care costs were
considered, including survivor costs or long-term costs of
encephalopathy.
Direct non-medical costs included lost productivity from time
missed from work due to hospitalization, and therefore applied
only to severe cases (Table 1). We estimated work loss based on
published estimates of hospital length of stay combined with
estimates of age-specific employment rates and mean wage
[23,29,30]. We did not consider the cost of productivity loss due
to days spent at home with illness, or lifetime productivity loss
among fatalities.
Analyses. Cumulative lifetime costs and QALYs were esti-
mated for each vaccine strategy. Cumulative costs are calculated
as the sum of costs of vaccination and associated adverse events,
and the costs of treating pertussis, including treatment costs and
work loss due to hospitalization; QALYs lost are calculated as the
sum of losses due to acute disease and losses to death or
encephalopathy. Costs incurred and QALYs gained after the first
year of the model were discounted at 3% per year. Incremental
cost-effectiveness ratios (ICERs) were calculated by dividing the
Figure 2. Economic model.
doi:10.1371/journal.pone.0067260.g002
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Table 1. Model inputs and sources for adults aged 65 years.
Parameter Value Scenario Analysis Values PSA Distribution (Values) Source
Disease Inputs
Incidence Range (per 100,000) 25 Uniform (Range:
25/ 100,000 –
200/100,000)
Assumptions based on CDC Morbidity
and Mortality Weekly Report 2009
(Vol.58/No.53), California Department
of Public Health Pertussis Report 2011
50
100
150
200
Coverage 10% Assumption
Tdap Efficacy 89% 77% Lognormal (95%
CI: 77.6%–94.6%)
Schmitt 1996
Duration of Protection 8 years 6, 10 years Uniform (Range: 4–10
years)
De Vries 2010
Population adults 65 years 2,592,176 U.S. Census Bureau 2010
Duration of Illness 87 days 56 days Lognormal (95% CI:
41.1–101.9)
Schmitt 1996
Duration of most severe symptoms 2 weeks 1 week Assumption
Proportion of cases that are severe 12.0% Varies by incidence
(12.0–14.1%)
Beta: (SE: 1.04%) Cortese 2007
Proportion of cases that are
moderate
74.0% Varies by incidence
(74.0–84.7%)
Residual of severe and mild disease
Proportion of cases that are mild 14.0% Varies by incidence
(1.1–14.0%)
Cortese 2007
Probability of encephalopathy (permanent
sequelae) among
severe cases
0.47% 0% Caro 2005
Probability of death among
severe cases
0.86% 0.43% Caro 2005
Proportion of unreported cases
that receive medical care
70.7% Molinari 2007
Economic Inputs
Additional Cost of Tdap Vaccine* $18.10 $16.16, $17.84 CDC vaccine price list 2010, Lee 2007
Cost of Treating Mild Case of
Pertussis
$99.22 $0 Physicians ’ Fee and Coding Guide
2010, Red Book 2010, McDowell 2009
Cost of Treating Moderate Case of
Pertussis
$203.13 $443.38 Lee 2000
Cost of Treating Severe Case of
Pertussis
$7,221.97 $443.38 Lognormal (95% CI:
$5,839– $37,572)
O ’Brien 2005
Days of work lost due
to hospitalization, reported cases
0.55 O ’Brien 2005, BLS Curent Population
Survey 2010
Value of lost productivity per day $114.30 $607.95** Gamma (SE: $23.42) Bureau of Labor Statistics 2010; Lee
2004
Utility Inputs
Disutility of pertussis with mild
symptoms
0.10 0.09, 0.08 Varied as fixed multiple
of severe
De Vries 2010
Disutility of pertussis with
moderate symptoms
0.15 0.14, 0.12 Varied as fixed multiple
of severe
De Vries 2010
Disutility of pertussis with
severe symptoms
0.19 0.17, 0.15 Beta (SE: 0.039) De Vries 2010
Disutility of encephalopathy 0.20 0.18, 0.16 Beta (SE: 0.007) Wells 2004
*Vaccine cost was estimated as the incremental cost of Tdap versus Td and included drug acquisition cost and cost of vaccine adverse events (Lee 2007).
**Cost is lost productivity per case and is applied to moderate and severe cases only.
PSA =probabilistic sensitivity analysis.
doi:10.1371/journal.pone.0067260.t001
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incremental cost of the Tdap strategy, compared to Td, by its
incremental benefit in terms of additional QALYs gained (i.e.,
reduction in QALYs lost).
In addition to the lifetime horizon, we examined results at 10
years post-vaccination. To assess the model results under different
parameter assumptions, scenario analyses were conducted with
increased vaccine price, reduced efficacy, reduced duration of
vaccine protection, reduced proportion with severe symptoms,
reduced mortality, reduced duration of symptoms, reduced
duration of moderate or severe disutility, no encephalopathy,
and reduced overall QALY decrements (by 10% and 20%). A
scenario analysis was also conducted using estimated direct
medical and direct non-medical treatment costs from alternative
published sources [12,31].
A second-order probabilistic Monte Carlo sensitivity analysis
(PSA) was conducted to assess the sensitivity of study findings to
overall parameter uncertainty, particularly with regard to vaccine
efficacy and waning, pertussis incidence and duration, costs, and
utilities. Uncertainty in key model parameters was characterized
by probability distributions with means equal to the base-case
estimates. Assumptions used in sensitivity analyses are summarized
in Table 1. Tdap efficacy was varied by varying the relative risk of
pertussis versus no vaccination based on the log-normal distribu-
tion, Parameters for which only a range was available were
assumed to follow either a uniform or a lognormal distribution.
Results
Depending on the incidence assumption, one-time vaccination
of a 10% cohort of adults aged 65 years is expected to result in
approximately 400 to 3,300 total pertussis cases avoided over the
lifetime of the vaccinated cohort (Table 2). Predicted total direct
medical cost savings ranged from approximately $360,000 at an
incidence of 25/100,000 to $2.9 million for an incidence of 200/
100,000; although the majority of cases prevented were of mild
and moderate severity, prevention of severe cases accounted for
.80% of the cost savings at all incidence levels (Table 3).
Predicted savings from direct non-medical costs were estimated to
comprise about 1% of the total cost savings; therefore, results from
the societal and payer perspectives did not differ greatly. The
estimated $4.69 million in vaccination costs was only partially
offset by cost savings from disease prevention. Prevention savings
ranged from less than 10% of vaccine costs at 25/100,000 to two-
thirds of the vaccine cost at 250/100.000; the vaccination program
was not cost-saving at any incidence level examined.
The cost-effectiveness results in terms of incremental cost per
case averted and per QALY gained from the societal perspective
are presented in Table 4. Introducing one-time Tdap vaccination
among a cohort of 10% of U.S. residents aged 65 years results in a
cost per case averted ranging from $10,500 to $538 and cost per
QALY gained ranging from $336,000 to $17,100, depending on
the incidence level, from the societal perspective. Analyses from
the payer perspective yielded similar results. Vaccinating adults
aged 65 years has an ICER of less than $50,000 per QALY gained
if pertussis incidence in adults is at least 116 cases/100,000, from
both the societal and payer perspectives.
A series of scenario and sensitivity analysis were conducted to
test various assumptions in the model (Table 5). For the scenario
assuming 77% Tdap efficacy, cost per QALY gained from the
societal perspective increased by 17% from the base-case at an
incidence of 25 per 100,000 and by 41% at an incidence of 200
per 100,000. When duration of protection was decreased,
incremental cost-effectiveness ratios (ICERs) per QALY gained
increased by 20% to 51% from the base-case societal perspective,
depending on incidence levels. Increasing the duration of
protection to 10 years caused the ICER to decrease from the
base-case societal perspective by 12% at an incidence of 25 per
100,000 and by 31% at an incidence of 200 per 100,000. Results
were most sensitive to the model time horizon, vaccine charac-
teristics (vaccine efficacy, duration of protection), and the
outcomes associated with severe cases (proportion severe, mortal-
Figure 3. Tdap waning vaccine efficacy.
doi:10.1371/journal.pone.0067260.g003
Table 2. Pertussis cases avoided by vaccinating 10% of US
population aged 65 years.
Incidence (per 100,000)
Case Type 25 50 100 150 200
Severe cases 49.3 98.6 197.1 295.7 394.2
Deaths 0.4 0.8 1.7 2.5 3.4
Encephalopathy 0.2 0.5 0.9 1.4 1.8
Moderate Cases 303.9 607.8 1,215.5 1,823.3 2,431.0
Mild Cases 57.5 115.0 230.0 344.9 459.9
Treated 40.6 81.2 162.5 243.7 325.0
Untreated 16.9 33.7 67.5 101.2 134.9
Total Cases 410.6 821.3 1,642.6 2,463.9 3,285.2
doi:10.1371/journal.pone.0067260.t002
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ity, utility decrement and duration of symptoms). The cost-
effectiveness ratio of vaccinating adults aged 65 years remained
less than $50,000/QALY gained at an incidence level of 150
cases/100,000 across all scenario analyses from the societal
perspective except when we reduced the proportion of severe
case by 50%, where it was $51,800/QALY gained.
The PSA using 1,000 simulations resulted in a distribution of
incremental costs and QALYs gained with a mean ICER of
$39,500 and 95% of ICER values falling between $28,900 and
$53,400 (Figure 4). In all simulations, both incremental costs and
QALYs were higher for the Tdap versus Td vaccination program.
Discussion
We constructed a cohort model to estimate the cases averted
and cost implications of replacing the decennial Td vaccine with
Tdap vaccine, in adults aged 65 years.
Model results were generated for incidence levels ranging from
25 cases/100,000 to 200 cases/100,000; vaccinating 10% of adults
aged 65 years resulted in an incremental cost per case averted of
approximately $500 to $10,500 and an incremental cost per
QALY gained of $17,200 to $336,100 from the societal
perspective, depending on incidence assumptions.
The findings of our study are based on a number of
assumptions, and limitations of the model should be considered
when interpreting results. First, the model considers only the
benefits of vaccination to the vaccinated individuals and does not
evaluate indirect effects (herd effects) from reduced transmission of
pertussis from protected individuals; A recently published analysis
by Coudeville and colleagues of vaccination among adults age
,65 using a dynamic transmission model [24], suggests that
including these effects would likely have made the results more
favorable for Tdap boosting. In addition, the model evaluates only
a 65-year-old cohort, whose outcomes cannot be extrapolated to
other age groups. A further study limitation is that data used to
estimate vaccine effectiveness were taken from immunogenicity
trials of DTaP in a pediatric population and may not reflect the
immune response expected in the 65 year old population.
Table 3. Incremental costs from vaccinating 10% of US population aged 65 years.
Incidence (per 100,000)
Cost Type 25 50 100 150 200
Direct Medical Cost (Savings)
Mild treated ($3,467) ($6,934) ($13,867) ($20,801) ($27,734)
Moderate ($53,088) ($106,177) ($212,354) ($318,531) ($424,707)
Severe ($306,083) ($612,167) ($1,224,334) ($1,836,500) ($2,448,667)
Total ($362,639) ($725,277) ($1,450,554) ($2,175,832) ($2,901,109)
Direct Non-Medical (Lost Productivity)
Cost (Savings)
Mild treated ($0) ($0) ($0) ($0) ($0)
Moderate ($0) ($0) ($0) ($0) ($0)
Severe ($3,102) ($6,205) ($12,409) ($18,614) ($24,819)
Total ($3,102) ($6,205) ($12,409) ($18,614) ($24,819)
Direct Medical and Direct
Non-Medical Cost (Savings)
($365,741) ($731,482) ($1,462,964) ($2,194,446) ($2,925,928)
Vaccination Cost $4,691,839 $4,691,839 $4,691,839 $4,691,839 $4,691,839
Total Costs Including Direct Non-
Medical Cost
$4,326,098 $3,960,357 $3,228,876 $2,497,393 $1,765,911
Total Costs Excluding Direct Non-
Medical Cost
$4,329,200 $3,966,562 $3,241,285 $2,516,007 $1,790,730
doi:10.1371/journal.pone.0067260.t003
Table 4. Incremental cost per case averted and per QALY gained (89% efficacy), societal perspective.
Incidence (cases/
100,000)
Cases
averted
Discounted
Incremental
costs
Discounted
Incremental
QALYs
Incremental Cost/
Case averted
Incremental Cost/QALY
gained
25 410.65 $4,326,102 12.87 $10,535 $336,108
50 821.29 $3,960,366 25.74 $4,822 $153,846
100 1,642.59 $3,228,893 51.48 $1,966 $62,716
150 2,463.88 $2,497,420 77.23 $1,014 $32,339
200 3,285.17 $1,765,947 102.97 $538 $17,150
doi:10.1371/journal.pone.0067260.t004
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Table 5. Scenario analyses, societal perspective.
Incremental Cost per QALY gained
Scenario
Analysis
Incidence 25/
100,000
Incidence 50/
100,000
Incidence 100/
100,000
Incidence 150/
100,000
Incidence 200/
100,000
Base case Scenario $336,108 $153,846 $62,716 $32,339 $17,150
Model horizon 10 years $393,277 $182,684 $77,387 $42,288 $24,739
Vaccine efficacy 77% $392,916 $182,250 $76,917 $41,806 $24,251
Duration of protection
6 Years
$404,039 $187,945 $79,897 $43,882 $25,874
No cases of
encephalopathy
$348,822 $159,666 $65,088 $33,562 $17,799
Mortality decreased by 50% $386,188 $176,769 $72,060 $37,157 $19,705
Reduce proportion of
severe cases by 50%
$409,440 $194,867 $87,580 $51,818 $33,937
Duration of protection 10 years $294,973 $133,178 $52,280 $25,314 $11,831
Public price for Tdap
vs. Td ($16.16)
$297,037 $134,311 $52,948 $25,827 $12,266
Mixed public and private price* ($17.84) $330,871 $151,228 $61,406 $31,466 $16,495
QALY decrement: 210% $362,950 $166,133 $67,724 $34,921 $18,519
QALY decrement: 220% $394,452 $180,552 $73,602 $37,952 $20,127
Duration of symptoms decreased
from 86 to
56 days
$438,013 $200,491 $81,730 $42,143 $22,350
Duration of moderate and severe
symptoms
decreased from 2 to
1 week
$344,757 $157,805 $64,329 $33,171 $17,591
Costing using Lee
2004 and 2007
$339,388 $157,126 $65,995 $35,618 $20,430
*Mixed public and private incremental vaccine cost was calculated by weighing the public and private vaccine cost by the proportion of those who receive the vaccine
at public cost.
doi:10.1371/journal.pone.0067260.t005
Figure 4. Probabilistic sensitivity analysis, societal perspective.
doi:10.1371/journal.pone.0067260.g004
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Scenario analyses showed the model was sensitive to lower efficacy
assumptions, but results remained favorable at similar incidence
levels as with the base case efficacy. We used data specific to the
65+ population in model estimation where available; however our
estimates for vaccine efficacy, duration of symptoms and utility
were derived from studies in younger populations and may not
reflect the experience of those aged 65+. We also note that the
population aged 65+ is treated as homogeneous and we did not
model natural immunity or potential changes in disease suscep-
tibility and outcome due to immunosenescence or comorbidity as
individuals age. Therefore, to the extent that vaccination at age 65
shifts disease to older age groups with worse outcomes, our analysis
may overstate the benefits of the vaccination program.
Pertussis incidence data showed a decreasing pattern after the
2005 adult and adolescent vaccination recommendation, followed
by an apparent increase in incidence thereafter [2]. The reason for
this recent increase in incidence is unclear and may represent
changes in reporting rather than in true incidence. Estimates from
recent outbreaks have shown great variability in reported cases.
Surveillance data from a California outbreak in 2010 reported
23.4 cases/100,000 residents, with reported rates ranging from
435.0/100,000 for infants aged ,6 months to 5.2 reported cases/
100,00 among those aged .65 [12]. In the recent pertussis
outbreak in Washington State, through June 2012 there were 39.3
reported pertussis cases/100,000 persons, with incidence ranging
from 4.9 cases per 100,000 to 425.8 cases per 100,000, across
counties reporting cases [13]. Due to this uncertainty in the true
incidence, we chose to assess outcomes across a range of incidence
values for our analyses. We note that in doing so, we chose
incidence levels that are all higher than CDC reported cases.
Because our severity estimates are based on reported cases, we
may be overestimating the severity of all pertussis cases if
unreported cases are milder than reported. We conducted
sensitivity analyses in which we decreased the proportion of severe
cases by 50% and found that results were indeed less favorable,
although still in the cost-effective range at higher incidence
assumptions. We recognize, therefore, that to the extent our
estimates over- or under-state the severity of pertussis cases, we
may be over-or under-estimating the potential savings in pertussis
treatment costs with the Tdap vaccination program.
In base-case analyses, we did not consider either the lifetime
future healthcare costs for diseases unrelated to pertussis or the net
lifetime consumption costs among pertussis survivors, as suggested
by Meltzer [32]. Inclusion of future unrelated healthcare costs is
considered to be optional and not part of the reference case in the
US or other countries outside Sweden; inclusion of future
consumption is not recommended in any current guidelines.
Neither cost is typically included in US cost-effectiveness analyses
of vaccines in older populations [33,34], nor in submissions to the
Advisory Committee on Immunization Practices of the Centers for
Disease Control and Prevention [35]. For these reasons, we did
not include these costs in our base-case analysis.
However, because the target population in our study is likely to
have relatively low labor force participation and high health care
costs, the lives saved by the vaccination program may be relatively
costly, in this sense, from a societal perspective. To assess the
potential impact of including future costs for the additional
survivors under the vaccination program, we first performed a
sensitivity analysis that incorporated the age-specific annual per
capita healthcare expenditure in the US estimated from a
published study [36]. The year 2000 estimates for ages 65 and
85 were inflated to 2010 $US ($11,471 and $11,450, respectively)
and the age-specific discounted yearly expenditures were applied
to survivors over the remainder of their expected lifetime. Adding
these future medical costs increases the ICERs from a societal
perspective slightly to $340,000 at an incidence of 25/100,000 and
to $21,000 at an incidence of 200/100,000. Considering total
expenditures of $36,802 per year among US residents aged .65
estimated from the US Bureau of Labor Statistics [37], increases
the ICERs to $349,000 and $30,000, respectively.
All estimates of costs and outcomes used in the model were
derived and synthesized from a variety of data sources, and this
process of interpretation and synthesis is subject to bias. We
recognize that different assumptions may have yielded different
results. We also note that model inputs were selected to reflect US
epidemiology, and outcomes were calculated based on US costs
life expectancy and age-specific utilities. Generalizing our results to
other settings, in particular those with substantially lower health-
care costs, should therefore be approached with caution.
Although no other published models have examined the cost-
effectiveness of vaccinating the U.S. population aged $65 years,
our findings are generally consistent with other studies that have
examined the cost-effectiveness of pertussis vaccination in other
age groups. For example Lee and colleagues evaluated both a one-
time and decennial vaccination strategy in adults aged 20–
64 years using a static Markov model and concluded that at
disease incidences of greater than 120 cases per 100,000
populations, both strategies are cost-effective at a $50,000/QALY
threshold [12].
A cost-effectiveness study of pertussis vaccination in adults aged
$65 years conducted by the CDC reported a cost per QALY
saved of $31,000 assuming an incidence rate of 104 cases/100,000
[11], while our study reports a cost/QALY of $63,000 per QALY
gained at an incidence rate of 100 cases/100,000. Differences in
base-case estimates, including vaccine efficacy, waning immunity,
medical costs, and duration of illness, likely contributed to the
difference in outcomes.
Because of the uncertainty and conflicting evidence about the
true pertussis incidence, our conclusion is conditional upon the
estimate of incidence. Using the best available efficacy and cost
information, our static model analysis suggests that when pertussis
incidence in adults $65 years is greater than 116 cases/100,000,
replacing Td with Tdap yields a cost-effectiveness ratio less than
$50,000/QALY gained from both the societal and payer
perspectives. Estimates of pertussis incidence from other sources
suggest that 116 cases/100,000 is a plausible estimate of pertussis
incidence [11]. Vaccinating those aged 65 years yields a cost-
effectiveness ratio similar to published estimates for adult
vaccination [12], and the model yields relatively stable results
under various scenario and sensitivity analyses.
Boostrix and Infanrix are trademarks of the GlaxoSmithKline
group of companies. Adacel is a trademark of Sanofi-Pasteur.
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